A hydration media for biological tissue products, methods of making the same and methods of using the same is provided. The hydration media includes sodium phosphate and calcium silicate and can be used to store or hydrate a biological tissue product.

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Disclosed are a stabilizer for storage of a biological sample, a composition for storage of a nucleic acid and/or a polypeptide in a biological sample under non-freezing conditions, a kit comprising the composition, a mixture comprising the composition and a biological sample, and a method for storage of a nucleic acid and/or a polypeptide in a biological sample under non-freezing conditions. The integrity and stability of the nucleic acid and/or polypeptide in a biological sample can be stored for a long time under non-freezing conditions by using the stabilizer according to the invention, and therefore the stabilizer has a good application prospect.

The present invention is related to corneal storage compositions comprising moxifloxacin and optionally, amphotericin B. The present invention is further directed to methods of storing viable corneal tissue comprising placing viable corneal tissue in a composition of the present invention.

A portable, ex vivo perfusion system for preserving detached biological tissue includes a receptacle for housing the tissue in a normothermic environment, a perfusion core to pump perfusate through the tissue via at least one conduit, at least one detection device to measure parameters during perfusion, and at least one parameter control device to maintain the parameter in a predetermined threshold. The system also include a controller with instructions to receive the measured parameters, compare the parameters to predetermined thresholds, and when the parameters are outside the thresholds change an output of the at least one parameter control device to get the parameters within the threshold and alert a user that parameters were outside the thresholds.

Methods for improving the functionality and/or fertility of sperm, for example, by enhancing motility and/or extending the lifespan of sperm by subjecting the isolated sperm to a starvation protocol and/or ionophore are provided. Such methods may be used in, for example, artificial insemination to reduce the number of sperm needed for insemination and to improve conception rates.

This invention is related to a compound with the structural formula (I)

##STR00001## wherein, R1, and R2 are independently selected from the group consisting of C.sub.1-C.sub.6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH.sub.2NHR.sub.9, C(?O)YR.sub.10, CH2OH

##STR00002##

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Processes are sequentially performed on a plurality of biological samples of an identical type from a reference time, and the plurality of biological samples are sequentially evaluated from a time point at which a preset time elapses from the reference time, in which a time interval of each process on each of the biological samples is set to a time interval which is equal to or more than a shortest process operation time of the processing apparatus, and a time interval of each evaluation of each of the biological samples is set to a time interval which is equal to or more than a shortest evaluation operation time of the evaluation apparatus and is obtained by adding or subtracting a desired time interval shorter than the shortest evaluation operation time to or from the time interval of each process.

A blood storage system comprising: a collection vessel for red blood cells; an oxygen or oxygen and carbon dioxide depletion device; a storage vessel for red blood cells; tubing connecting the collection vessel to the oxygen or oxygen and carbon dioxide depletion device and the oxygen or oxygen and carbon dioxide depletion device to the storage vessel; and a gamma or X-ray irradiating device is used to irradiate red blood cells stored in the vessel, storing red blood cells under anaerobic conditions.